INVO Bioscience, Inc., a commercial-stage fertility company, has entered an exclusive distribution agreement with Onesky Holdings Limited (Onesky) for Mainland China (excludes Hong Kong, Macau and Taiwan).
Onesky will be responsible to register the product in the country, and upon government approval, will be obligated to purchase minimum quantities of INVOcell totalling approximately $14 million over the initial five-year term after approval. Customary additional terms and conditions apply, including term renewals.
